Please wait while we load the requested 10-K report or click the link below:
|For Immediate Release||Contact: Brandi Simpson|
|Sr. Director, Investor Relations|
|NPS Pharmaceuticals, Inc.|
NPS PHARMACEUTICALS REPORTS
FOURTH QUARTER AND YEAR-END OPERATING RESULTS
Salt Lake City February 16, 2006 NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) today announced its operating results for the fourth quarter and year ended December 31, 2005 and reviewed the companys progress last year.
The companys accomplishments in 2005 included:
|||Filing the PREOS® (parathyroid hormone [rDNA origin] for injection) new drug application (NDA) in the United States and the Preotact marketing authorization application (MAA) in Europe;|
|||Building a commercial sales organization to promote partnered products Kineret® (anakinra) and Restasis® (cyclosporine ophthalmic emulsion) and to prepare for the launch of PREOS®;|
|||Completing the teduglutide Phase IIa study in Crohns disease; and|
|||Appointing new executives, including president and COO, Dr. Tony Coles.|
NPS CEO and chairman Dr. Hunter Jackson stated, In 2005 NPS continued its transformation from a research and development company to an integrated pharmaceutical enterprise by building a commercial sales and marketing capability while continuing to develop our pipeline. This year we look forward to launching PREOS if it is approved, advancing our pipeline, and moving a new product into preclinical development.
The following information was filed by Nps Pharmaceuticals Inc (NPSP) on Thursday, February 16, 2006 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Nps Pharmaceuticals Inc's financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Nps Pharmaceuticals Inc.